OBJECTIVE: Growing evidence suggests increasing frequencies of autoimmunity and certain autoimmune diseases, but findings are limited by the lack of systematic data and evolving approaches and definitions. This study was undertaken to investigate whether the prevalence of antinuclear antibodies (ANA), the most common biomarker of autoimmunity, changed over a recent 25-year span in the US. METHODS: Serum ANA were measured by standard indirect immunofluorescence assays on HEp-2 cells in 14,211 participants age ≥12 years from the National Health and Nutrition Examination Survey, with approximately one-third from each of 3 time periods: 1988-1991, 1999-2004, and 2011-2012. We used logistic regression adjusted for sex, age, race/ethnicity, and survey design variables to estimate changes in ANA prevalence across the time periods. RESULTS: The prevalence of ANA was 11.0% (95% confidence interval [95% CI] 9.7-12.6%) in 1988-1991, 11.5% (95% CI 10.3-12.8%) in 1999-2004, and 15.9% (95% CI 14.3-17.6%) in 2011-2012 (P for trend < 0.0001), which corresponds to ~22 million, ~27 million, and ~41 million affected individuals, respectively. Among adolescents age 12-19 years, ANA prevalence increased substantially, with odds ratios (ORs) of 2.02 (95% CI 1.16-3.53) and 2.88 (95% CI 1.64-5.04) in the second and third time periods relative to the first (P for trend < 0.0001). ANA prevalence increased in both sexes (especially in men), older adults (age ≥50 years), and non-Hispanic whites. These increases in ANA prevalence were not explained by concurrent trends in weight (obesity/overweight), smoking exposure, or alcohol consumption. CONCLUSION: The prevalence of ANA in the US has increased considerably in recent years. Additional studies to determine factors underlying these increases in ANA prevalence could elucidate causes of autoimmunity and enable the development of preventative measures.
OBJECTIVE: Growing evidence suggests increasing frequencies of autoimmunity and certain autoimmune diseases, but findings are limited by the lack of systematic data and evolving approaches and definitions. This study was undertaken to investigate whether the prevalence of antinuclear antibodies (ANA), the most common biomarker of autoimmunity, changed over a recent 25-year span in the US. METHODS: Serum ANA were measured by standard indirect immunofluorescence assays on HEp-2 cells in 14,211 participants age ≥12 years from the National Health and Nutrition Examination Survey, with approximately one-third from each of 3 time periods: 1988-1991, 1999-2004, and 2011-2012. We used logistic regression adjusted for sex, age, race/ethnicity, and survey design variables to estimate changes in ANA prevalence across the time periods. RESULTS: The prevalence of ANA was 11.0% (95% confidence interval [95% CI] 9.7-12.6%) in 1988-1991, 11.5% (95% CI 10.3-12.8%) in 1999-2004, and 15.9% (95% CI 14.3-17.6%) in 2011-2012 (P for trend < 0.0001), which corresponds to ~22 million, ~27 million, and ~41 million affected individuals, respectively. Among adolescents age 12-19 years, ANA prevalence increased substantially, with odds ratios (ORs) of 2.02 (95% CI 1.16-3.53) and 2.88 (95% CI 1.64-5.04) in the second and third time periods relative to the first (P for trend < 0.0001). ANA prevalence increased in both sexes (especially in men), older adults (age ≥50 years), and non-Hispanic whites. These increases in ANA prevalence were not explained by concurrent trends in weight (obesity/overweight), smoking exposure, or alcohol consumption. CONCLUSION: The prevalence of ANA in the US has increased considerably in recent years. Additional studies to determine factors underlying these increases in ANA prevalence could elucidate causes of autoimmunity and enable the development of preventative measures.
Authors: Elizabeth J Mayer-Davis; Jean M Lawrence; Dana Dabelea; Jasmin Divers; Scott Isom; Lawrence Dolan; Giuseppina Imperatore; Barbara Linder; Santica Marcovina; David J Pettitt; Catherine Pihoker; Sharon Saydah; Lynne Wagenknecht Journal: N Engl J Med Date: 2017-04-13 Impact factor: 91.245
Authors: Medha Barbhaiya; Bing Lu; Jeffrey A Sparks; Susan Malspeis; Shun-Chiao Chang; Elizabeth W Karlson; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2017-03 Impact factor: 4.794
Authors: Nithya Lingampalli; Jeremy Sokolove; Lauren J Lahey; Jess D Edison; William R Gilliland; V Michael Holers; Kevin D Deane; William H Robinson Journal: Clin Immunol Date: 2018-05-26 Impact factor: 3.969
Authors: Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley Journal: N Engl J Med Date: 2003-10-16 Impact factor: 91.245
Authors: Christine G Parks; Frederick W Miller; Minoru Satoh; Edward K L Chan; Zhanna Andrushchenko; Linda S Birnbaum; Todd A Jusko; Grace E Kissling; Mehul D Patel; Kathryn M Rose; Clarice Weinberg; Darryl C Zeldin; Dale P Sandler Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08-01 Impact factor: 4.254
Authors: Jan Damoiseaux; Luis Eduardo Coelho Andrade; Orlando Gabriel Carballo; Karsten Conrad; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Ignacio Garcia de la Torre; Manfred Herold; Werner Klotz; Wilson de Melo Cruvinel; Tsuneyo Mimori; Carlos von Muhlen; Minoru Satoh; Edward K Chan Journal: Ann Rheum Dis Date: 2019-03-12 Impact factor: 19.103
Authors: Gregg E Dinse; Todd A Jusko; Irene Z Whitt; Caroll A Co; Christine G Parks; Minoru Satoh; Edward K L Chan; Kathryn M Rose; Nigel J Walker; Linda S Birnbaum; Darryl C Zeldin; Clarice R Weinberg; Frederick W Miller Journal: Environ Health Perspect Date: 2015-08-07 Impact factor: 9.031
Authors: Wilton Ferreira Silva Santos; Ana Paula de Castro Cantuária; Daniele de Castro Félix; Leandro Kegler Nardes; Igor Cabral Santos de Melo Journal: Adv Rheumatol Date: 2022-08-15
Authors: Elizabeth R Zhang; Ruth M Pfeiffer; April Austin; Megan A Clarke; Jennifer Hayes; Marie-Josèphe Horner; Analise Monterosso; Karen S Pawlish; Eric A Engels; Meredith S Shiels Journal: J Natl Cancer Inst Date: 2022-09-09 Impact factor: 11.816
Authors: Karlinde Amber Spit; Miranda Scharff; Christel Jm de Blok; Frank B Niessen; Yara Bachour; Prabath W Nanayakkara Journal: BMJ Open Date: 2022-06-09 Impact factor: 3.006